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Background: Toll-like receptors (TLRs) on T cells can modulate their responses, however, the extent and
significance of TLR expression by lung T cells, NK cells, or NKT cells in chronic obstructive pulmonary disease
(COPD) is unknown.
Methods: Lung tissue collected from clinically-indicated resections (n = 34) was used either: (a) to compare the
expression of TLR1, TLR2, TLR2/1, TLR3, TLR4, TLR5, TLR6 and TLR9 on lung CD8+ T cells, CD4+ T cells, NK cells and
NKT cells from smokers with or without COPD; or (b) to isolate CD8+ T cells for culture with anti-CD3ε without or
with various TLR ligands. We measured protein expression of IFN-γ, TNF-α, IL-13, perforin, granzyme A, granzyme B,
soluble FasL, CCL2, CCL3, CCL4, CCL5, CCL11, and CXCL9 in supernatants.
Results: All the lung subsets analyzed demonstrated low levels of specific TLR expression, but the percentage of CD8+
T cells expressing TLR1, TLR2, TLR4, TLR6 and TLR2/1 was significantly increased in COPD subjects relative to those
without COPD. In contrast, from the same subjects, only TLR2/1 and TLR2 on lung CD4+ T cells and CD8+ NKT cells,
respectively, showed a significant increase in COPD and there was no difference in TLR expression on lung CD56+ NK
cells. Production of the Tc1 cytokines IFN-γ and TNF-.alpha; by lung CD8+ T cells were significantly increased
via co-stimulation by Pam3CSK4, a specific TLR2/1 ligand, but not by other agonists. Furthermore, this increase in
cytokine production was specific to lung CD8+ T cells from patients with COPD as compared to lung CD8+ T cells
from smokers without COPD.
Conclusions: These data suggest that as lung function worsens in COPD, the auto-aggressive behavior of lung CD8+ T
cells could increase in response to microbial TLR ligands, specifically ligands against TLR2/1.
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Chronic obstructive pulmonary disease (COPD), the 3rd
leading cause of death in the United States, is a chronic,
debilitating disease with a rapidly increasing incidence
[1]. Although COPD is recognized to have important
systemic manifestations [2], its principal pathological
changes occur in the lungs and include irreversible lung
destruction, airways remodeling, mucus hypersecretion,
and inflammatory cell infiltration [3]. This infiltration is
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reproduction in any medium, provided the orneutrophils, and CD8+ T cells in the lungs. CD8+ T cells
have been implicated in COPD pathogenesis primarily
because their numbers in lung parenchyma and small
airways correlate inversely with forced expiratory volume
in one second (FEV1) [4,5], the modality most frequently
used to define COPD severity. We have previously
shown that lung CD8+ T cell mRNA transcripts for
IFN-γ, perforin, and granzyme B correlate inversely to
FEV1% predicted [6,7]. Based on the ability of CD8+ T
cells to kill cells that they recognize as infected or
damaged, and to secrete cytokines that can recruit and
activate additional inflammatory cells, CD8+ T cells have
considerable potential to damage lung parenchyma.
Nevertheless, despite support in murine models [8,9],
there is no direct evidence that human lung CD8+ Tal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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what mechanisms drive this amplified CD8 response in
the minority of smokers who develop COPD.
The function of lung CD4+ T cells, natural killer (NK)
cells and natural killer T (NKT) cells in COPD has been
less widely studied. There is evidence that numbers of
CD4+ T cells and NK cells, but not of NK T cells, also
increase in the lung as the disease progresses [3,10,11].
In peripheral blood, the cytotoxic effector function of
NK and NKT cells appears to be impaired and their rela-
tive number to be reduced in COPD subjects [12,13].
However, the same investigators later demonstrated that
NK and NKT cells collected from the sputum were both
higher as a proportion of all leukocytes and more cyto-
toxic in COPD subjects than in healthy smokers or non-
smoking healthy subjects [14]. A similar finding was also
very recently reported for NK and NKT cells in the
bronchoalveolar lavage fluid from individuals with
COPD [15]. As NK and NKT cells can be a potent
source of cytokines and cytotoxic molecules, an increase
in their number or improper effector function could
contribute to COPD pathology.
Recent data from both human and murine studies have
revealed that Toll-like receptors (TLRs), originally
described on innate immune cells, also modulate T cell
responses. mRNA for TLR1, TLR2, TLR3, TLR4, TLR5,
TLR7 and TLR9 has been detected in human peripheral
blood T cells, although at greatly varying levels [16]. En-
gagement of TLRs on T cells lowered the activation thres-
hold for co-stimulatory signals delivered by antigen-
presenting cells [16-18]. TLR3 and TLR9 stimulation
enhanced the survival of activated murine CD4+ T cells,
without augmenting their proliferation [18]. IFN-γ produc-
tion was increased by stimulation via TLR3 or TLR4 in
human CD8+ T cells [19,20] and via TLR5 or TLR7/8 in
human cells positive for CD45RO, which would consist
predominately of memory T cells [16]. Evidence also
suggests that TLR stimulation of CD8+ T cells enhances
their cytotoxicity. Co-stimulating activated T cells with
TLR2 ligands upregulated granzyme B secretion and cyto-
toxic activity [17]. Furthermore, TLR3 and TLR9 ligands
induced fully efficient cytotoxic responses by murine CD8+
T cells, overriding the requirement for CD4+ T cell help
[21]. In contrast, a different study found that engagement
of TLR3 on human CD8+ T cells had no effect on their
cytolytic activity [19]. Human peripheral blood NK cells re-
portedly express high levels of TLR3, TLR7, and TLR9 and
stimulation with ligands led to an increase in IFN-γ pro-
duction [22]. In a mouse model of COPD, NK cells from
smoke-exposed mice produced more IFN-γ following
stimulation with the ligands for TLR3, TLR7, and TLR9
than NK cells from mice exposed to filtered air [23].
By contrast, relatively little is know about the expres-
sion of TLRs by lung T cells, NK cells, or NKT cells inCOPD. In endobronchial biopsies, TLR4 and TLR9 ex-
pression was increased on CD8+ T cells of subjects with
COPD as compared to control subjects. Stimulation of
peripheral blood CD8+ T cells with cigarette smoke con-
densate led to increases in TNF-α and IL-10, that were
attenuated following TLR4 or TLR9 inhibition [24]. How-
ever, the role of other TLRs or specific TLR agonists was
not explored.
Based on the ongoing colonization of the lower airways
in COPD by microbial pathogens, we hypothesize that
modulation from TLR signaling could contribute to the
exaggerated pathogenic response of lung CD8+ T cells in
COPD. To test this hypothesis, we used flow cytometry to
analyze TLR expression on lung CD8+ T cells (CD3+
CD8+ CD56-), CD4+ T cells (CD3+ CD4+ CD56-), NK
cells (CD3- CD56+ CD4- CD8-), CD4 NKT cells (CD3+
CD56+ CD4+ CD8-) and CD8 NKT cells (CD3+ CD56+
CD8+ CD4-). After observing increases in the TLR expres-
sion on CD8+ T cells from COPD subjects compared to
subjects with normal pulmonary function, we assessed the
functional relevance of this expression by stimulating
isolated CD8+ Tcells with TLR ligands and measuring pro-
duction of cytokines, cytotoxic molecules, and chemokines.
Our data show that human lung CD8+ T cells responded
to TLR agonists, in particular the TLR2/1 agonist
Pam3CSK4, by increasing production of cytokines and
chemokines in response to TCR stimulation.
Methods
Specimens and patient population
Consented subjects undergoing clinically-indicated re-
sections for pulmonary nodules, lung volume reduction
surgery, or lung transplantation were recruited from
the University of Michigan Health System and the VA
Ann Arbor Healthcare System. Studies and consent
procedures were approved by Institutional Review
Boards. All subjects (n = 34) gave written consent pre-
operatively and underwent preoperative spirometry, pro-
spectively collected medication history and clinical
evaluation by a pulmonologist. Available non-contrast-
enhanced CT scans (n = 13) were analyzed for
percent emphysema using 3D Slicer software (www.
airwayinspector.org) at a threshold of < −950 Hounsfield
units. We categorized subjects using the 2008 classifica-
tion of the Global Initiative for Chronic Obstructive
Lung Disease (GOLD) [25]. Subjects (n = 14) with a
smoking history of 10 pack years or greater, a ratio of
forced expiratory volume in 1 second to forced vital cap-
acity (FEV1/FVC) >0.70, normal spirometry, and no clin-
ical diagnosis of COPD represent smoking controls (S).
Subjects (n = 20) with a smoking history, defined as
greater than 10 pack years, FEV1/FVC <0.7 and abnor-
mal spirometry were considered to have COPD. Table 1
shows the male-to-female ratio, age, smoking history,
Table 1 Summary of subject demographics, smoking
histories, spirometry and emphysema
Group S COPD p value
Subjects, n 14 20
Sex ratio, M/F 11/3 12/8 NS
Age, years (SD) 62 (9) 62 (11) NS
Smoking, pack-years (SD) 60 (29) 62 (41) NS
Smoking status (Active/Former) 6/8 5/15 NS
FEV1,% pred (SD) 91 (16) 40 (27) <0.0001
Emphysema,% (SD) 12 (14) 36 (15) 0.02
Surgical indication (resection/LVRS/transplant) 14/0/0 8/5/7 0.001
ICS use (yes/no) 1/13 14/6 0.0004
Recent infection (yes/no) 0/14 2/18 NS
Data are presented as average (SD), except for sex and smoking status ratios.
Former smokers were defined as those subjects that had quit smoking for
more than 6 months. Subjects were considered to have a recent infection if
they had taken a course of antibiotics in the past 6 weeks. S, smoker without
COPD; M, male; F, female; LVRS, lung volume reduction surgery; ICS, inhaled
corticosteroids; NS, not significant.
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tegories. Former smokers were defined as those subjects
who had quit smoking for greater than 6 months.
Studies and consent procedures were performed in ac-
cordance with the Declaration of Helsinki at the VA
Ann Arbor Healthcare System and the University of
Michigan Health System and were approved by the Insti-
tutional Review Board at each site (FWA 00000348 and
FWA 00004969, respectively).
Sample preparation and flow cytometric analysis
Under the supervision of a Pathologist, in cases of no-
dule resection, only parenchymal, non-neoplastic lung
tissue remote from the nodules and lacking post-
obstructive changes was collected. In the cases of ex-
planted lungs, tissue from the distal region of the lung
was collected. Lung specimens were immediately stored
in fresh RPMI and kept at 4°C until processed. Lung
sections weighing approximately 3 g were dispersed
using a Waring blender without enzyme treatments,
which we have previously shown produces single cell
suspensions of high viability and functional capacity [6].
Importantly, not all types of experiments were performed
on tissue from every subject, due to limitations in the size
of some samples.
For flow cytometry, cells were filtered through a 40 μm
strainer to remove debris and were resuspended in staining
buffer (2% FBS in PBS). Cells were added in a volume
of 100 μl to each flow tube. We used monoclonal anti-
bodies against the following antigens (clones shown in pa-
rentheses): CD45 (HI30), CD3 (UCHT1), CD4 (OKT4),
CD8 (OKT8), CD56 (MEM-188), TLR1 (GD2.F4), TLR2
(T2.5), TLR3 (TLR3.7), TLR4 (HTA125), TLR6 (hPer6),
TLR9 (eB72-1665), (eBioscience, San Diego, CA), and
TLR5 (85B152.5) (Abcam, Cambridge, MA). Appropriateisotype-matched controls were used in all experiments.
Antibodies were conjugated to either fluorescein isothio-
cyanate (FITC), phycoerythrin (PE), phycoerythrin-cyanine
7 (PE-Cy7), allophycocyanin (APC), allophycocyanin-
cyanine 7 (APC-Cy7), Pacific Blue, Alexa Fluor 700, or
biotin, with the biotinylated antibodies developed using
streptavidin-phycoerythrin-cyanine 5 (SA-PE-Cy5), as
shown in Table 2.
To evaluate cell viability by flow cytometry, we used
LIVE/DEADW Fixable Dead Cell Stain Kit (Life Technolo-
gies) in Aqua. This reactive dye permeates the membranes
of necrotic cells, resulting in positive fluorescent staining.
This procedure is also compatible with intracellular
staining. Cells were first incubated in the dark with the
LIVE/DEADW Fixable dye for 30 minutes, washed, and
then incubated with primary antibodies and secondary
reagents for 25 minutes each at room temperature, with
washing between incubations. We measured intracellular
expression of the endosomal receptors TLR3 and TLR9,
after cell fixation and permeabilization. Cells were
analyzed on an LSR II flow cytometer (BD Bioscience, San
Jose, CA) equipped with 488 nm blue, 405 nm violet,
633 nm red lasers. Data were collected using FACS Diva
software with automatic compensation, and were analyzed
using FlowJo software (Tree Star, Inc., Ashland, OR). A
minimum of 10,000 viable (cells that are negative for the
Aqua Live/Dead fluorescence) CD45+ events were
collected per sample.
In vitro stimulation
In separate experiments, CD8+ CD56- T cells were
isolated from lung tissue by sequentially incubating the
single-cell suspension with magnetic beads (Miltenyi
Biotec, Auburn, CA). Samples were first incubated with
CD56 magnetic beads for 15 minutes at 4°C and posi-
tively selected using MACS LS columns (Miltenyi
Biotec). The remaining CD56 negative cells, which no
longer contained NK cells, were then incubated with
CD8 magnetic beads and positively selected using
MACS LS columns. In these experiments, viability was
determined by Trypan blue exclusion. CD8+ cells were
cultured in 96-well flat-bottom plates at a density of
50,000 viable cells per 200 μl lymphocyte culture me-
dia (10% FBS, 1 mM sodium pyruvate, 0.5 mM
2-Mercaptoethanol, 1 mM HEPES, 100 u/ml penicillin,
100 u/ml streptomycin, 0.292 mg/ml L-Glutamine in
RPMI). Cells were stimulated with media alone, with
plate-bound anti-CD3ε (5 μg/ml) alone, or with anti-
CD3ε plus each of the following TLR ligands:
Pam3CSK4 (1 μg/ml), Heat-killed Listeria monocytogenes
(HKLM; 108 organisms/ml), Poly(I:C) (10 μg/ml), LPS E.
coli K12 (1 μg/ml), Flagellin Salmonella typhimurium
(1 μg/ml), FSL-1 (1 μg/ml), Imiquimod (1 μg/ml), ssRNA
40 (1 μg/ml), or ODN 2006, type B (5 μM) (all agonists
Table 2 Antibody staining panel
Fluorochrome 1 2 3 4 5 6
FITC M IgG2a TLR5 CD45 CD45 CD45 CD45
PE IC:M IgG1 IC:TLR3 M IgG1 TLR1 IC:R IgG2a IC:TLR9
Biotin (PE-Cy5) R IgG2a TLR6
PE-Cy7 CD45 CD45 M IgG1 TLR2 M IgG2a TLR4
APC M IgG2a CD56 M IgG2a CD56 M IgG2a CD56
APC-Cy7 M IgG1 CD3 M IgG1 CD3 M IgG1 CD3
Pacific Blue M IgG2a CD8 M IgG2a CD8 M IgG2a CD8
Alexa Fluor 700 M IgG2b CD4 M IgG2b CD4 M IgG2b CD4
Aqua (AmCyan) Live/Dead Live/Dead Live/Dead Live/Dead Live/Dead Live/Dead
M, mouse; R, rat; IC, intra-cellular.
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37°C and 5% CO2 for 48 hours, at which point super-
natants were collected for analysis.
Protein analysis of culture supernatants
Cell culture supernatants were collected and stored
at −20°C until analyzed. Using the Luminex 200 system
(Luminex Corporation, Austin, TX), protein levels for
IFN-γ, TNF-α, IL-13, perforin, granzyme A, granzyme B,
soluble Fas ligand, (Biolegend, San Diego, CA) and CCL2,
CCL3, CCL4, CCL5, CCL11, and CXCL9 (Invitrogen,
Carlsbad, CA) were determined according to manufac-
turer’s instructions.
Statistics
Statistical analysis was performed using SAS 9.1 statis-
tical software (SAS Institute Inc., Cary, NC) and
GraphPad Prism (GraphPad Software, Inc., La Jolla, CA).
The Mann–Whitney t-test was used to compare TLR ex-
pression between subjects with COPD and subjects with
normal pulmonary function. Kruskal-Wallis tests were
used to look for significant differences between TLR-
ligand treatment groups. Nonparametric (Spearman)
correlation analysis was used to determine the correl-
ation coefficient, rS. Both linear and log transformed
outcomes were considered. Multivariate regression
examined the statistically significant relationships,
adjusting for age and smoking exposure (pack years). A
two-tailed p value of < 0.05 was considered to indicate
significance.
Results
Identification of CD8+ T cell, CD4+ T cell, and NK cell
subsets in human lung tissue
To determine whether lung T cells, NK cells and NK T
cells express TLRs, we used 9-color flow cytometry to
analyze expression of TLR1, TLR2/1, TLR2, TLR3, TLR4,
TLR5, TLR6 and TLR9 on unpurified lung leukocytes
from 28 subjects. We assessed both surface and intra-
cellular expression of TLR3 and TLR9. We identifiedfive different lymphocyte populations, including CD8+
T cells, CD4+ T cells, NK cells, CD8+ NKT cells, and
CD4+ NKT cells. To identify these populations, we first
gated on CD45+ low side scatter cells (Figure 1A) and
then selected cells that were either CD3+ or CD3-
(Figure 1B). NK cells were defined as CD3- CD56+
CD4- CD8- cells (Figure 1C, E). CD8+ T cells were
defined as being CD3+ CD8+ CD56-, while CD8+ NKT
cells were CD3+ CD8+ CD56+ (Figure 1D, F). Similarly,
CD4+ T cells were defined as CD3+ CD4+ CD56- cells
and CD4+ NKT cells were CD3+ CD4+ CD56+
(Figure 1D, G). We saw no difference in the frequency
of any of the cell types when comparing healthy smokers
to COPD subjects (data not shown). On average, the fre-
quency as a percent of CD45+ cells was 7.6% for CD8+
T cells, 8.8% for CD4+ T cells, 5.0% for NK cells, 1.3%
for CD8+ NKT cells, and 0.6% for CD4+ NKT cells.
Increased percentage of lung CD8+ T cells expressing
TLRs in COPD and emphysema
After gating on our cell population of interest, we used a
5% probability contour plot to select positive events, as
distinguished from negative events by the isotype con-
trol. With this strategy, we were able to determine the
percentage of CD8+ T cells, CD4+ T cells, NK cells and
NK T cells that expressed a given TLR. Analysis of the
TLR expression on 28 subjects (n = 10 subjects with nor-
mal pulmonary function, n = 18 subjects with COPD)
revealed that the percentage of lung CD8+ T cells
expressing TLR1, TLR2, TLR4, TLR6, and TLR2/1 was
significantly increased in subjects with COPD compared
to the subjects without COPD (Figure 2 and Figure 3,
left panel). Lung CD8+ T cells also expressed TLR3,
TLR5, and TLR9 (~10% of cells), but the percentage of
positive cells did not show a significant difference be-
tween subject groups (data not shown). Interestingly, in
contrast to the CD8+ T cell findings, although CD4+ T
cells, CD56+ NK cells and NKT cells were analyzed sim-
ultaneously in the same sample, only the expression of
TLR2/1 on the lung CD4+ T cells and the expression of
Figure 1 Gating strategy used to identify T cells, NK cells, and NKT cells isolated from human lung tissue. Lung tissue was dispersed and
stained with CD45, CD3, CD8, CD4, and CD56 monoclonal antibodies to identify various cell subsets. (A) Viable CD45+ cells with a low side
scatter profile were selected; (B) cells were further divided into CD3- and CD3+ fractions; (C) CD56+ cells were selected from the CD3- fraction
and (E) NK cells were selected by excluding CD4 and CD8. (D) CD8+ and CD4+ cells were identified and (F) CD56+ was used to separate CD8+
NKT cells from CD8+ T cells and (G) CD4+ NKT cells from CD4+ T cells. Appropriate isotype-matched controls for all antibodies were used to
determine positive staining.
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in the subjects with COPD (Figure 3, middle and right
panels; data not shown for NKT cells). As shown in the
subject demographics (Table 1), healthy smokers and
subjects with COPD showed significant differences in
their clinical indication for surgery and their inhaled cor-
ticosteroid (ICS) use. To ensure that the presence oflung cancer or ICS use were not responsible for the dif-
ference in TLR expression between healthy smokers and
COPD subjects, we analyzed these parameters in the
COPD cohort. We saw no difference in TLR expression
when the subjects with COPD were stratified by surgical
indication or ICS use, suggesting that these variables are
not contributing to the difference in TLR expression.
Figure 2 Representative histograms demonstrating an increase
in TLR expression on lung CD8+ T cells in COPD. CD8+ CD56-
cells from human lung tissue were identified as described in the
legend to Figure 1 and examined for TLR expression. Left panels are
representative histograms (A, C, E, G) or density plot (I) from
smokers without COPD and right panels are representative
histograms (B, D, F, H) or density plot (J) from subjects with COPD.
Expression of (A, B) TLR1, (C, D) TLR2, (E, F) TLR4, (G, H) TLR6, and (I,
J) TLR2/1 are shown. Shaded profile, isotype staining; open profiles,
antibody-specific staining.
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correlation with percent emphysema, calculated from
non-contrast computed tomography (CT) scans that
were available for 13 patients. The percentage of lung
CD8+ T cells expressing TLR5 and TLR2/1 increased
with worsening emphysema (Table 3 and Figure 4A,B).
Similarly, NK cells expressing TLR5, TLR6, and TLR2/1
also correlated with worsening emphysema as deter-
mined by CT quantification (Table 3 and Figure 4C-E).
The magnitude and direction of these correlations re-
mained similar, although significance was attenuated after
adjustment for age and smoking status as independent
variables. The expression of TLRs on lung CD4+ T cells
and NKT cells did not correlate with percent emphysema,
implying that the regulation of TLRs within the lung
environment in a given patient differs between lympho-
cyte subsets.
TLR stimulation of lung CD8+ T cells results in increased
cytokine production
Based on our previous finding that human lung CD8+ T
cell transcripts for IFN-γ, perforin, and granzyme B are
increased in later stages of COPD [6,7], we hypothesized
that augmented production of these molecules might re-
sult from TLR-mediated response to danger signals in the
lung environment. To test this hypothesis, CD8+ CD56- T
cells isolated from lung tissue of COPD subjects were
stimulated in vitro with plate-bound anti-CD3ε, plus each
of the following TLR ligands: Pam3CSK4, heat-killed
Listeria monocytogenes (HKLM), Poly(I:C), LPS, Flagellin,
FSL-1, Imiquimod, ssRNA40, ODN 2006. Cells were
stimulated for 48 hours and then supernatants were
collected for protein analysis. Multiplex beads were used
to measure IFN-γ, TNF-α, IL-13, perforin, granzyme A,
granzyme B, and soluble fas ligand. Only Pam3CSK4, the
ligand for TLR2/1, induced significant increases in IFN-γ
and TNF-α (Figure 5A,B). Due to variability in baseline
response between individual subjects, we first analyzed
results expressed as the fold-change compared to the con-
trol stimulated with anti-CD3ε alone (n = 7). None of the
other agonists induced significant increases in expression
(HKLM, LPS, and Flagellin shown in Figure 5A-C; results
not shown for Poly(I:C), FSL-1, Imiquimod, ssRNA40,
or ODN 2006). Furthermore, the effect of TLR2/1
Figure 3 Percentage of CD8+ T cells expressing bacterial TLRs is increased in COPD subjects. Lung tissue was dispersed and stained with
monoclonal antibodies to measure TLR expression on CD8+ T cells (left panels), CD4+ T cells (middle panels), or CD56+ NK cells (right panels)
from smokers without COPD (S; blue circles; n = 10) and with COPD (COPD; red circles; n = 18). The vertical axis shows the percentage of cells
expressing a given TLR. Open circles represent individual patients. Lines represent the mean ± SEM. The Mann Whitney t-test was used to
determine significant differences between groups. *, p < 0.05, **, p < 0.01.
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as there was no increase in either IL-13 (Figure 5C) or
cytotoxic molecules (data not shown). Stimulation of the
lung CD8+ Tcells with the TLR2/1 agonist Pam3CSK4 also
resulted in a 3-fold increase in the chemokine CCL3
(Figure 5D). No significant differences were observed in the
other chemokines measured (CCL2, CCL4, CCL5, CCL11
and CXCL9). No increase in protein levels over the un-
stimulated control was seen when lung CD8+ T cells were
cultured with TLR ligands in the absence of anti-CD3ε
(data not shown), suggesting that TLRs function solely asco-stimulatory molecules, as has been reported, and do not
independently activate lung T cells. Of the seven COPD
subjects used in these in vitro experiments, three had lung
resections and four were explants; six subjects were taking
ICS. Thus, although surgical indication did not appear
to play a role in the increase production of IFN-γ,
TNF-α, and CCL3, we are unable to rule out a possible ef-
fect of the ICS. The absolute values for IFN-γ, TNF-α,
IL-13, and CCL3 are also shown (Figure 5E-H). Following
stimulation with anti-CD3ε and Pam3CSK4, IFN-γ and
CCL3 averaged 4,000 pg/mL, which was 10-fold higher
Table 3 Summary of correlation between percentage of
lung subsets expressing TLRs and emphysema score
Subset TLR rS Value p Value
CD8+ TLR1 0.54 0.09
T Cells TLR2 0.59 0.06
TLR4 0.37 0.23
TLR5 0.62 0.03
TLR6 0.59 0.05
TLR2/1 0.70 0.01
CD4+ TLR1 0.09 0.77
T cells TLR2 0.52 0.09
TLR4 0.11 0.72
TLR5 0.30 0.32
TLR6 0.21 0.50
TLR2/1 0.27 0.39
CD56+ TLR1 0.51 0.09
NK cells TLR2 0.47 0.12
TLR4 0.35 0.24
TLR5 0.64 0.02
TLR6 0.60 0.04
TLR2/1 0.63 0.03
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Although there is an increase in the average of IFN-γ,
TNF-α, and CCL3 following stimulation with Pam3CSK4,
the data did not achieve statistical significance, due to the
marked variation in baseline response between individual
subjects.
Finally, to determine whether the increase in IFN-γ,
TNF-α and CCL3 following TLR2/1 stimulation was specific
to lung CD8+ T cells from COPD subjects, we also exposed
lung CD8+ CD56- cells from control subjects to Pam3CSK4
(Figure 6A-D). Lung CD8+ T cells from COPD sub-
jects (n = 7) produced significantly more IFN-γ and
TNF-α than CD8+ T cells from control subjects (n= 5). No
difference was seen in the production of IL-13 or CCL3.
These results suggest that in COPD, the increased number
of lung CD8+ T cells expressing TLR2/1 are able to con-
tribute to an augmented inflammatory response following
TLR2/1 stimulation. The absolute values for IFN-TNF-α,
IL-13, and CCL3 are shown (Figure 6E-H).Discussion
The principal results of this analysis of TLR molecules
on human lung T cells, NK cells and NKT cells demon-
strate for the first time several observations relevant to
COPD pathogenesis. First, expression of multiple TLRs
on lung CD8+ T cells (but not on simultaneously
analyzed lung CD4+ T cells, NK cells or NKT cells) was
increased in COPD patients relative to smokers withpreserved lung function. Second, TLR2/1 molecules
expressed by lung CD8+ T cells were functional, as
shown by the markedly enhanced production of
cytokines linked to lung inflammation and COPD pro-
gression following co-stimulation by the TLR2/1 agonist
in vitro. Third, expression by lung CD8+ T cells of TLR
2/1 and TLR5 correlated significantly with quantitative
emphysema scores in univariate analysis. Collectively,
these findings strengthen the evidence linking lung
CD8+ T cells to smoking-induced lung destruction in
susceptible cigarette smokers.
The finding that an increased percentage of lung
CD8+ T cells express TLR1, TLR2, TLR2/1, TLR4 and
TLR6 in COPD subjects extends to human lung paren-
chyma and to a specific disease state the results of previ-
ous studies of peripheral blood from healthy humans
[16,19,20,26,27]. Although many TLRs have multiple
ligands, it is noteworthy that increased expression was
seen in the cell surface receptors most strongly
associated with bacterial recognition (TLR1, TLR2,
TLR2/1, TLR4 and TLR6), and not in the endosomal
receptors TLR3 or TLR9, which recognize viruses and
endogenous danger signals [28]. Furthermore, the very
strong correlation between TLR5 or TLR2/1 and emphy-
sema severity suggests that TLRs on lung CD8+ T cells
may be specifically contributing to the pathogenesis of
emphysema and highlights the importance of defining
specific COPD phenotypes in selecting patients for
personalized therapies [29]. Additional experiments will
be needed to determine whether the co-stimulatory ef-
fect of TLR ligation is additive or synergistic when mul-
tiple TLRs are stimulated simultaneously, as would
plausibly occur during exacerbations of COPD. Neither
the presence of lung cancer nor recent infections
appeared to contribute to the difference in TLR expres-
sion that we observed between healthy subjects and
COPD subjects. Little is known about the effect of
glucocorticoids on TLRs, but it has been shown that
dexamethasone, in combination with IFN-γ or TNF-α,
was able to synergistically enhance TLR2 expression on
respiratory epithelial cells [30]; however in a separate
study, dexamethasone was shown to downregulate TLR4
expression in an airway epithelial cell line [31]. The ef-
fect of steroids on TLRs has not been investigated in T
cells. In our study, we saw no difference in TLR expres-
sion when ICS use was evaluated.
Although we also detected expression of multiple
TLRs on lung CD4+ T cells, the near complete lack of
their increased expression on this cell type in COPD,
relative to age-matched smokers with preserved spirom-
etry, implies either that the regulation or significance of
TLR expression on CD4+ lung T cells, or the role of that
subset itself, differs in COPD from that of lung CD8+ T
cells. It is interesting that on the CD56+ NK cells, TLR5,
Figure 4 Expression of TLR5 and TLR2/1 on lung CD8+ T cells
and NK cells increases with worsening emphysema. Lung tissue
was stained with monoclonal antibodies to measure TLR expression
on T cells, NK cells, and NKT cells. Expression (vertical axis) of (A)
TLR5 on CD8+ T cells, (B) TLR2/1 on CD8+ T cells, (C) TLR5 on NK
cells, (D) TLR6 on NK cells, (E) TLR2/1 on NK cells, stratified by
percent emphysema (−950 HU threshold) (horizontal axis). Open
circles represent individual patients, n = 13. Spearman non-
parametric analysis was used to calculate the rS value.
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physema severity but showed no difference between
COPD subjects and controls. These finding are compat-
ible with the suggestion by Borchers and colleagues [32]
that NK cells are particularly crucial in emphysema
pathogenesis. Collectively, our findings support previous
studies [33-37] on the importance of adaptive immune
responses in emphysematous lung destruction. Whether
TLR expression is restricted to specific CD8+ T cell
clones, especially those with autoreactivity, will require
further study, although the rather low fraction of total
lung CD8+ expressing TLRs in the current study would
be compatible with that possibility.
Lung CD8+ T cells in COPD appear especially sensi-
tive to stimulation through the TLR2/1 heterodimer, as
shown by the results of co-stimulation by the specific
agonist Pam3CSK4. Our findings extend to the human
system the finding that murine ovalbumin-specific OT-1
cytotoxic T lymphocytes responded to TLR2/1 stimula-
tion with increased levels of IFN-γ at both the RNA and
protein levels [38]. TLR2 is known to recognize the most
diverse repertoire of microbe-associated patterns, in part
through its unique ability to heterodimerize with either
TLR1 or TLR6. TLR2/1 heterodimers are primarily
responsible for recognizing triacylated lipoproteins,
such as the outer membrane proteins of nontypeable
Haemophilus influenzae (NTHI) [39]. This organism is
one of the predominant bacterial pathogens associated
with airway infection in COPD, both in stable disease
and as an important infectious trigger of exacerbations
[40,41]. Although the presence of TLR2/1 on lung CD8+
T cells might play a role in host defense in early COPD,
repeated cycles of infection could swing the balance
from host defense to inappropriate activation and subse-
quent tissue damage. Importantly, NTHI can be an
intracellular pathogen of respiratory epithelial cells and
macrophages [42,43], suggesting the possibility for pres-
entation both of NTHI-derived antigens in the context
of class I MHC molecules and of their lipoproteins to
TLR2/1 on lung CD8+ T cells. A recent study by King and
colleagues used live NTHI to stimulate T cells from the
lungs of COPD subjects and control subjects [44]. They
found that both CD4+ and CD8+ T cells from COPD
subjects produced significantly higher levels of TNF-α,
Figure 5 Stimulation of TLR2/1 on lung CD8+ T cells increases production of IFN-γ TNF-.alpha; and CCL3. CD8+ T cells were isolated from
lung tissue of COPD patients (n = 7) and cultured for 48 hours with anti-CD3ε alone or with addition of specific ligands for the following TLRs
(in parentheses): Pam3CSK4 (TLR2/1), HKLM (TLR2), LPS (TLR4), and Flagellin (TLR5). Supernatants were measured using multiplex beads for
(A, E) IFN-γ, (B, F) TNF-α, (C, G) IL-13, and (D, H) CCL3. (A-D) Results are expressed as the fold change in protein concentration over
the control stimulated with anti-CD3ε alone (represented by dashed line) or (E-H) as absolute values of protein. Bars represent the mean ± SEM.
Kruskal-Wallis One-way ANOVA was used to look for differences between groups. *, p < 0.05, compared to the control.
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to confirm whether TLRs have a role in this response.
The range of effector molecules significantly increa-
sed by co-stimulation via TLR2/1 (IFN-γ, TNF-α and
the chemokine CCL3) is also intriguing. Transgenic
overexpression of IFN-γ in the lungs induces productionFigure 6 Lung CD8+ T cells from COPD subjects have increased prod
without COPD. A-D, CD8+ T cells were isolated from lung tissue of smoke
subjects with COPD (n = 7) and cultured with anti-CD3ε plus Pam3CSK4 for
(A, E) IFN-γ, (B, F) TNF-α, and (C, G) IL-13 and (D, H) CCL3. (A-D) Results ar
over the control stimulated with anti-CD3ε alone (represented by dashed lin
The Mann–Whitney t-test was used to compare control versus COPD subjectsof matrix metalloproteinases by macrophages and deve-
lopment of emphysema in a murine model [45], Si-
milarly, a central role for TNF-α in smoking-induced
emphysema development is well-supported by data from
murine models [46-48], likely reflecting in part the abi-
lity of TNF-α to activate endothelial cells to increaseuction of IFN-γ and TNF-.alpha; than CD8+ T cells from subjects
rs without COPD (S, n = 5) for comparison to CD8+ T cells from
48 hours. Supernatants were measured using multiplex beads for
e expressed as the fold change in protein concentration
e) or (E-H) as absolute values of protein. Bars represent the mean ± SEM.
. *, p < 0.05, compared to the control.
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known as MIP-1α) is a ligand for the chemokine
receptors CCR1 and CCR5, and we previously showed
that expression of CCR5 by lung CD8+ T cells increases
with spirometrically-defined COPD severity [6]. Hence,
stimulation via TLR2/1 and possibly other TLRs could
generate a positive feed-back loop via CCR5 inducing
the accumulation of lung CD8+ T cells seen in COPD.
Collectively, the current results agree with our pre-
vious finding that lung CD8+ T cells in COPD have a
Tc1 phenotype and lack Tc2 cytokine secretion, even
following TCR-dependent or TCR-independent stimu-
lation [7]. The practical importance of the small,
statistically insignificant increases in IL-13 protein pro-
duction following stimulation with flagellin is questio-
nable, because its concentration was so much lower
than that of IFN-γ (100-fold less) and TNF-α (10-fold
less). Because we had previously shown that perforin
and granzyme B transcripts from lung CD8+ T cells
were increased in severe COPD [7], we were surprised
to see that TLR-stimulation did not increase production
of perforin or granzyme B. It is possible that perforin
and granzyme were increased in the intracellular gra-
nules of the CD8+ T cells but release of these molecules
into the supernatant requires CD8+ degranulation. If the
CD8+ T cells did not degranulate, then any increases in
perforin or granzyme B would only be detectable with
intracellular flow cytometry, which we did not perform
in these particular experiments.
Our results differ in several respects from a previous
study by Nadigel and colleagues, which found that both
TLR4 and TLR9 were increased on lung CD8+ T cells
from COPD patients [24], relative to healthy control
subjects with normal spirometry who included two ex-
smokers and three never-smokers. Although our study
confirmed the finding of increased TLR4 expression, we
did not see an increase in TLR9 expression in COPD
relative to our reference population, who were entirely
active smokers or ex-smokers. Furthermore, in our ana-
lysis, the percentage of lung CD8+ T cells expressing
TLR4 only modestly increased in COPD, whereas they
saw an increase from 20% in the control lung tissue to
90% in the COPD lung tissue [24]. These differences can
likely be attributed to the tissue sample and techniques
that were used. Nadigel et al. used immunofluorescence
microscopy to analyze TLR expression of CD8+ T cells
in endobronchial biopsies (i.e., relatively large airways)
[24]. We used flow cytometry, which permits very ob-
jective quantification of specific staining relative to
isotype control antibody, and we analyzed dispersed tis-
sue from the distal lung compartment. CD8+ T cells are
present in the central and peripheral airways and lung
parenchyma in COPD, but the number of CD8+ T cells
in the distal airways negatively correlates with airflowobstruction in patients with COPD [49], suggesting that
this is a key location in COPD pathogenesis [3].
It is well documented that TLRs are expressed prom-
inently on antigen-presenting cells, such as dendritic
cells, and therefore play an important, if indirect, role in
the initiation of adaptive T cell responses. TLR expres-
sion by macrophages and B cells can also contribute to
production of antibodies and of chemokines. It is less
clear whether the direct signaling of TLRs on T cells has
the same physiological importance. On the one hand,
the requirement for stimulation via the TCR, shown in
this study and others, implies that TLRs are serving a
primarily co-stimulatory role in CD8+ T cells. Indeed,
numerous studies have shown that a number of TLR
ligands can provide co-stimulatory signals to T cells,
even in the absence of CD28 engagement [16-20]. Add-
itional studies have suggested that TLR signaling
through myeloid differentiation protein 88 (MyD88) may
increase the clonal expansion and survival of activated T
cells [50,51]. Conversely, the other lung cell types that
express TLRs (dendritic cells, macrophages, B cells and
epithelial cells) cannot produce IFN-γ, a unique cytokine
that has both protective and potentially damaging prop-
erties. Thus, the current findings collectively suggest that
lung CD8+ T cells use TLRs to sense and respond to
microenvironmental conditions and to receive additional
signals at the site of injury.
Conclusions
In summary, human lung CD8+ T cells seem able to re-
spond to danger signals in their environment, especially
bacterial colonization of the lower respiratory tract, by
up-regulating their potential to produce inflammatory
mediators and cytotoxic molecules when stimulated via
their cognate antigen receptors. Together with progres-
sive upregulation of TLRs on lung CD8+ T cells as
COPD worsens, this mechanism could contribute to
lung destruction during respiratory infections.
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